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Background: Solitary Fibrous Tumor is a rare type of soft tissue tumor of intermediate malignant potential which
may recur or metastasize in 15-20% of cases. Data on the management of patients with advanced SFT is scarce:
chemotherapy has been described as ineffective, while recent data suggests that anti-angiogenic therapies may be
more efficient.
Methods: We conducted a retrospective study on patients treated for advanced SFT at a single institution: from
January 1994 to December 2011, 30 patients were treated in the Centre Léon Bérard for an advanced SFT.
Results: Twenty-three patients received cytotoxic chemotherapy as first-line therapy. Best responses were 2 (9%)
partial responses, 13 (57%) stable diseases (SD) and 8 (35%) progressive diseases (PD). Median Progression Free
Survival (PFS) was 5.2 (95% CI: 3.2-7.1) months and 9 patients were free of progression at 6 months. Ten patients
received an anti-angiogenic treatment (sunitinib or pazopanib) as a 2nd, 3rd or 4th line. Best responses were 5 SD
and 5 PD; median PFS was 5.1 months (95% CI 0.7-9.6). Four patients (36%) were progression-free for more
than 6 months. Two patients receiving pazopanib were without progression at 6 and 8 months and two
patients receiving sunitinib were free of progression at 30 months.
Conclusion: Response rate with standard chemotherapy was low and PFS appear similar between cytotoxic
chemotherapy and anti-angiogenic agents.Background
Solitary fibrous tumor (SFT) is a rare type of soft tissue
tumor that was during many decades, assimilated to
hemangiopericytoma (HPC). However, with time it
became clear that the diagnostic criteria for
hemangiopericytoma were too loose to adequately re-
flect reality. Therefore, the last World Health
Organization classification published in 2006 identi-
fies SFT as a distinctive entity. While true HPC still
exists, its definition is now more specific and delin-
eated [1,2]. Finally, sarcomas with hemangiopericytic
features are separated from HPC and SFT. Initially
described as a mesothelial pleural lesion, SFT is now
recognized to arise in ubiquitous anatomical sites
and may occur both in mesothelial tissues (pleura,* Correspondence: cassierp@hotmail.com
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reproduction in any medium, provided the orperitoneum, pericardium) and soft tissues or visceral
organs (lung, meninges, thigh, thyroid, etc.,) [3]. It
generally follows a benign clinical course. Neverthe-
less, according to Park and Araujo [4], it may recur
either locally or at distant sites in 15 to 20% of the
patients. Although criteria were defined to help clini-
cians differentiate malignant lesions from more be-
nign ones, predicting the clinical course of these rare
lesions remains challenging. In most cases, malignant
lesion are characterized by large tumor size, high mi-
totic index (more than 4 mitoses per 10 high-power
fields), nuclear pleomorphism, high cellularity and
the presence of necrosis and/or hemorrhage [5].
However, the relationship between histological fea-
tures and clinical behavior of SFT is not so clear and
these tumors still have unpredictable course.
When SFT is localized, one of the most important
prognostic factor is the quality of the initial excision,
with free margins [6]. Thus, the ten-year overall survival
rate varies between 54 and 89% between series [7,8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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metastases occur, chemotherapy and/or radiotherapy
can be proposed as palliative treatments. Data on the
role of chemotherapy in the treatment of patients with
advanced SFT is currently limited to small retrospective
studies. In most of these studies, the drugs are those
used for treatment of soft tissue sarcomas (STS) such
as anthracyclines with or without ifosfamide [9,10],
trabectedin [11], and gemcitabine combined with
docetaxel. More recently, several case-reports and small
series have suggested that anti-angiogenic drugs may
have activity in SFT. Park et al. reported in 2009 their
experience on 14 patients treated with bevacizumab
combined with temozolomide. Based on Choi criteria
[12], 11 patients had a partial response (PR), 2 had
stable disease (SD) and 1 had progressive disease (PD)
as their best response. However only 2 patients in this
study achieved a PR based on RECIST [13]. Case-
reports of patients achieving long term tumor control
with sunitinib, sorafenib [14], or imatinib [15] have
been published. In the present study we sought to as-
sess the outcome of patients with advanced inoperable
SFT managed at our institution with standard chemo-
therapy and anti-angiogenic agents.
Methods
This retrospective study was approved by the ethics com-
mittee CPP Lyon Est IV. The Centre Léon Bérard (CLB)
sarcoma database was searched for patients with a diag-
nosis of SFT. Two hundred and thirty three patients’ files
were identified between January 1994 and December
2011. The vast majority of these patients were registered
in the CLB database for histology review or multidiscip-
linary meeting discussion but only 66 patients were actu-
ally managed at the CLB, of which 30 had advanced
disease and are the subject of this report.
Data were extracted from individual patients’ files and
analysed. All cases were reviewed by an expert patholo-
gist in the field of sarcomas (DR). Patients and tumor
characteristics were described using the median and
range for continuous variables and percentages with
95% Confidence Interval (95% CI) for categorical vari-
ables. Response was assessed using RECIST 1.0 [16]
and described as a response rate (RR) defined as the
percentage of patients with PR or complete response
(CR). Overall survival (OS) was defined as the time
from the date of diagnosis of advanced disease to the
date of death from any cause. Progression-free survival
(PFS) was calculated from the date a systemic treatment
was started to the date of disease progression or death
of any cause, whichever occurred first. Survival times
were plotted using the Kaplan-Meier method and com-
pared using the log-rank test. P-values of 0.05 or less
were considered statistically significant.Results
Patients’ characteristics
Thirty patients were identified as having advanced dis-
ease of which 18 were males. The median age at initial
diagnosis was 57.7 (range 24.7-83.3) years, while age at
diagnosis of advanced inoperable disease was 62.3 (range
34.7-87.2) years. The primary tumor was localised in
pleura (n=14, 47%), pelvis (n=4, 13%), meninges or cere-
bellum (n=3, 10%), limb (n=3, 10%), visceral organs (sig-
moid and bladder, n=2, 7%), spine (n=2, 7%), peritoneum
(n=1, 3%) and mediastinum (n=1, 3%). Twenty five pa-
tients underwent surgical resection of their primary
tumor, while five (17%) had unresectable disease at pres-
entation. Seventeen patients had metastatic disease and
the most common sites of metastasis were the lung (n=9,
53%), pleura (n=5, 29%) or peritoneum (n=3, 18%) but
liver, bone and lymph node metastases were also noted.
Of these 17 patients, 5 had metastases at the time of
presentation while 12 developed metastasis during
follow-up (median time from initial diagnosis 47.9
months; range 12.0 – 215.6 months). The main patient
characteristics are summarized in Table 1.
For 13 patients the initial diagnosis was not that of
SFT and for most of these patients the diagnosis of SFT
was made at relapse. In these cases, the following diag-
noses were initially raised: fibroma (n=3, 23%), gastro-
intestinal stromal tumor (GIST, n=2), mesothelioma
(n=2, 15%), fibrosarcoma (n=1, 8%), leiomyosarcoma
(n=1, 8%), angiosarcoma (n=1, 8%), histiofibrocytoma
(n=1, 8%), hamartochondroma (n=1, 8%), and meningi-
oma (n=1, 8%). After a median follow-up of 109 months
for surviving patients, 21 patients had died, 19 from pro-
gression of SFT, one from a treatment related complica-
tion (thrombotic event during anti-angiogenic therapy)
and one from unknown cause, and 3 patients were lost
to follow-up at 4.6, 11.8 and 144.7 months of follow-up.
The median overall survival for the whole cohort (n=30)
was 33.5 months (95% CI 14.2-52.8) from the date of
advanced inoperable disease (Figure 1).
First line treatment
Of the 30 patients, 3 received radiotherapy only, 2 pa-
tients benefitted from surgery, 2 patients from imatinib
and 23 received chemotherapy as first-line treatment.
Three patients received radiotherapy as their sole treat-
ment modality, in most cases for locally advanced disease
without metastases. The first patient was a 55-year old
lady with a skull-base SFT who had a partial response
after radiotherapy and was still alive and progression-free
after 70 months of follow-up. The second patient was a
67-year old gentleman with a skull-base SFT who experi-
enced disease progression shortly (2 months) after the
completion of therapy, did not received further therapy
and was lost to follow-up 4 months after the completion





Age, median (range) (yrs
At initial diagnosis 57.7 (24.7 – 83.3)
























Levard et al. BMC Cancer 2013, 13:109 Page 3 of 7
http://www.biomedcentral.com/1471-2407/13/109of radiotherapy. The third patient was an 81-year old
gentleman who had a recurring pleural SFT (after 2 oper-
ations), had stable disease after radiotherapy but had dis-
ease progression 19 months after the completion of
radiotherapy and died shortly after (22 months). Two pa-
tients who had R2 resection of pleural SFT and were
deemed not re-operable were offered pseudo-adjuvant
chemotherapy. Both had disease progression 5 and 26
months after the completion of chemotherapy and were
then offered pazopanib. Two patients who were initially
diagnosed as GISTs received imatinib as first line treat-
ment; both had disease-progression after 3 months of
treatment. One of these patients underwent surgical exci-
sion of his disease because of symptomatic uncontrolled
hypoglycaemia and was lost to follow-up shortly after;
pathological analysis of the surgical samples allowed
correcting the diagnosis to that of SFT. Because of thepoor response to imatinib, the second patient underwent
a percutaneous, ultrasound-guided biopsy of his pelvic
mass, on which the diagnosis of SFT was done (and no
KIT or PDGFRA mutation was found). This patient re-
ceived sunitinib as second-line therapy and had stable
disease for 30 months.
Response to first line cytotoxic chemotherapy
Twenty-three patients received cytotoxic chemotherapy
as their first-line of treatment for advanced measurable
disease (therefore excluding the 2 patients who received
pseudo-adjuvant chemotherapy): 14 were male and 9
were female. Their median age at the time of treatment
start was 65 (range 37–86) years old. Main characteris-
tics of patients who benefited from first-line cytotoxic
chemotherapy are indicated in Table 2. First line
consisted in a doxorubicin-based regimen for 19 patients
that were treated with either doxorubicin alone (n=9),
pegylated liposomal doxorubicin (n=1) or a doxorubicin
based combination (with ifosfamide n=8 or palifosfamide
n=1). The 4 other patients received vinorelbine (n=1),
paclitaxel (n=1), carboplatin and paclitaxel (n=1) and
brostallicin (n=1).
Overall, only 2 PR were observed (RR = 9%), both
in patients receiving doxorubicin-based chemotherapy
(1 treated with single agent doxorubicin and 1 treated
with both doxorubicin and ifosfamide). Thirteen pa-
tients (57%) had SD while 8 (35%) had PD as their
best response and nine patients (39%) were free of
progression at 6 months.
The median PFS was 5.2 (95% CI 3.2-7.1) months
and improved when both doxorubicin and ifosfamide
were combined (6.7 months) compared to single agent
doxorubicin (4.0 months) or other agents (1.0 month),
(p = 0.031) (Figure 2).
Using cytotoxic chemotherapy, the main adverse ef-
fects identified were grade 4 neutropenia (doxorubicin
alone, n=2; doxorubicin and ifosfamide, n=2), grade 4
thrombopenia (doxorubicin and ifosfamide, n=2), grade
3 anemia (doxorubicin and ifosfamide, n=1), pulmon-
ary embolism (1 patient treated with doxorubicin and
ifosfamide) and one patient had doxorubicin-induced
grade 3 congestive heart failure.
Other lines of therapy
Twenty one patients received second line therapy, in
12 patients second line treatment was cytotoxic ther-
apy: trabectedin (n=5), gemcitabine (n=3), doxorubicin
(n=1), brostallicin (n=1), ifosfamide (n=1) and cisplatin
(n=1). The 9 other patients received targeted therapies
consisting of imatinib (n=1), pazopanib (n=4), sunitinib
(n=2) or other investigational agents (n=2). Follow-up
information was not available for one patient and me-
dian PFS was 3.4 months (95% CI: 2.2-4.7).
Table 2 Characteristics of patients who received first-line cytotoxic chemotherapy










1 Pleura R1 150 Metastatic Surgery (3) AI 6,9 / 22,2
2 Peritoneum R0 100 Metastatic No AI 14,5 / 70,8
3 Pleura R1 12 Metastatic No AI 5,2 / 29
4 Tip N 0 Locally advanced No PLD 1,7 / 6,4
5 Pleura R1 20 Metastatic No Adriamycine 1,4 / 22,4
6 Cerebellum Unk 128 Metastatic Surgery (1) Brostallicin 4,8 / 34,5
7 Pelvic N 0 Metastatic Radiotherapy Adriamycine 9,3 / 32,8
8 Pleura R0 20 Metastatic Surgery (1) AI 2,4 / 21,2
9 Mediastinum N 0 Locally advanced No MAID 9,1 / 12,4
10 Pleura Unk 52 Locally advanced Surgery (1) Adriamycine 60 / 68,8
11 Shoulder R1 16 Locally advanced No AI 9 / 19,4
12 Pelvic R0 0 Metastatic No Adriamycine 1,5 / 5,7
13 Pleura R2 200 Locally advanced Surgery (1) Adriamycine-Palifosfamide 6,7 – 10,7
14 Pelvic R0 156 Locally advanced No Adriamycine 17,5 / 50,8
15 Pleura R0 11 Metastatic No Adriamycine 2,1 / 2,7
16 Spine Unk 96 Locally advanced Surgery (1) AI 5,9 / 60
17 Tip N 0 Metastatic No Adriamycine 4 / 4
18 Spine R2 120 Metastatic Surgery (1) and RT AI 2,9 / 32,3
19 Pleura R1 216 Metastatic Surgery (1) and RT Adriamycine 12,5 / 27,3
20 Pleura R1 12 Locally advanced No Carboplatin-Paclitaxel 1,0 / 2,1
21 Bladder R0 32 Metastatic No Brostallicin 1,8 / 1,9
22 Pleura R0 27 Metastatic No Paclitaxel 0,4 / 0,4
23 Pleura Unk 64 Metastatic Surgery (2) Vinorelbin 5,2 / 64,5
AI: Adriamycin-Ifosfamide; PLD: Pegylated Liposomal Doxorubicin; Unk: Unknown; RT: Radiotherapy; MAID: mesna, adriamycin, ifosfamide and dacarbazine; Surgery (number of surgeries).
Figure 1 Overall survival for the whole cohort (n=30).
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Figure 2 Progression-Free Survival for patients receiving first-line chemotherapy (n=23) (Panel A) and according to the type of
chemotherapy (Panel B).
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http://www.biomedcentral.com/1471-2407/13/109Fourteen patients received third line therapy:
gemcitabine (n= 4), trabectedin (n=3), vinorelbine (n=1),
pazopanib (n=2), doxorubicin (n=1), etoposide (n=1),
cisplatin (n=1) and other investigational agents (n=2).
Their median PFS was 4.3 months (95% CI: 1.7-6.8).
Six patients received a fourth line of systemic therapy:
sunitinib (n=2), gemcitabine-docetaxel combination
(n=2), trabectedin (n=1) and weekly doxorubicin (n=1).
Three patients received fifth line therapy: trabectedin
(n=1), weekly paclitaxel (n=1) and metronomic oral
cyclophosphamide (n=1).Response to anti-angiogenic treatment
Ten patients received an anti-angiogenic drug (Table 3):
6 received pazopanib (800 mg once daily) while 4 re-
ceived sunitinib (37.5 mg once daily). These oral TKI
were administered as second line in most patients (n=6)
while 4 patients received an anti-angiogenic TKI as 3rd
and 4th lines (2 patients each). There were no objective
response observed and 5 patients had SD as their best
response (3 of 4 treated with sunitinib and 2 of 6
treated with pazopanib). The median PFS on anti-
angiogenic was 5.1 months (95% CI 0.0-13.4) (Figure 3)
Table 3 Anti-angiogenic treatments




1 Sunitinib 4 SD 30 34
2 Pazopanib 3 SD 8 15
3 Pazopanib 2 PD 2 4
4 Sunitinib 4 PD 2 5
5 Pazopanib 2 SD 14 19
6 Pazopanib 2 PD 0,3 0,3
7 Pazopanib 3 PD 2 5
8 Sunitinib 2 SD 2 33
9 Sunitinib 2 SD 30 50
10 Pazopanib 2 PD 4 34
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than 6 months at 8.0 and 14.0 (pazopanib), and 29.5
and 29.9 months (sunitinib).
One patient died because of a thrombotic event during
the first month of treatment with pazopanib. Elevated
liver enzymes (ALT and/or AST) grade 3, anorexia grade
3 and anemia grade 3 were described in three patients
receiving pazopanib (one each). Grade 3 sunitinib-
induced diarrhea and heart failure were seen in the same
patient resulting in discontinuation of the agent.Discussion
SFT are rare tumors, especially in the advanced phase as
only a minority of patients will eventually recur after pri-
mary surgical management. Therefore data regarding the
actual effectiveness of systemic therapy in this setting is
limited and stems from small retrospective studies. OurFigure 3 Progression-Free Survival for patients treated with anti-angiaim in this study was to gain further knowledge on pa-
tients with SFT managed at our institution and add to
the current body of literature on the subject. As anti-
angiogenic therapy appears promising in the manage-
ment of patients with advanced SFT and standard
chemotherapy was reported to have limited efficacy we
chose to describe both of these approaches separately.
As first line therapy, most patients received a
doxorubicin-based regimen similar to patients with soft tis-
sue sarcomas (STS). Indeed, despite an important and well
known heterogeneity, most STS subgroups are managed
similarly, thus data are extrapolated to SFT and
doxorubicin-based regimen appears as a standard in the
first-line setting. However, the response rate in our series is
low but appears comparable to previously reported data
[9]. As previously noted, toxicity is not negligible. Combin-
ation therapy may increase response rate but has not been
showed to increase OS in patients with STS. Several pa-
tients in our series received subsequent lines of chemother-
apy, in most cases trabectedin and gemcitabine. In this
setting, some patients derived some benefit in terms of
tumor control as demonstrated by the median PFS, al-
though no RECIST-defined response was seen.
However, because the efficacy of standard chemotherapy
is limited in STS, much hope has grown around the devel-
opment of targeted therapies. In line with this, patients re-
ceiving anti-angiogenic agents such as pazopanib and
sunitinib derived some benefit from therapy. Although no
partial response was noted, tumor control appeared similar
to that of first line chemotherapy (PFS = 5.1 months versus
5.2 months) and appeared longer than that seen with sec-
ond or third-line chemotherapy, although no statistical
comparison was made. Furthermore, several patientsogenic agents (n=10).
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which remained on anti-angiogenic therapy for more than
a year. These results are comparable to those reported by
Stacchiotti et al. [17], who treated 35 patients with ad-
vanced SFT most of whom were pre-treated with chemo-
therapy (25 of 35) with sunitinib 37.5 mg daily. The
median duration of the treatment was 5 months (1 week-
27 months). Response rate with RECIST assessment was
6.5% (2 of 31 assessable patients had a PR). Seventeen pa-
tients had SD (54%) and 12 had PD (39.5%) as their best
response. The median PFS was 6 months (CI 95% 4.03-
8.01) and median OS was 16 months (CI 95% 12.07- 25.9).
One patient had a response that lasted 22 months. In an-
other phase II study evaluating sunitinib in 48 patients with
non-GIST sarcomas. In another phase II study evaluating
sunitinib in 48 patients with non-GIST sarcomas the over-
all RECIST response rate was 2%. Three of these 48 pa-
tients had SFT. No partial or complete response was
reported but long-lasting stable disease were observed for
24 and 58 weeks in 2 patients [18,19]. Another case-report
described a 4-months stable disease with sunitinib 50mg
daily for a woman with peritoneal progressive disease.
Treatment was discontinued because of toxicity but disease
control was maintained for more than 6 months after the
end of the treatment [14]. In a recently reported phase II
study conducted by the French Sarcoma Group 5 patients
with malignant SFT were treated with sorafenib: none had
a PR or CR [20].
Overall our data underline the modest activity of
standard chemotherapy in SFT, nevertheless PFS and RR
do not appear significantly lower that what is commonly
observed in other STS subtypes. Furthermore, although
anti-angiogenic agents have interesting activity in SFT
our data and those reported by others suggest that this
subtype is only modestly more sensitive than other sub-
types of sarcoma. This however would need to be
assessed in a prospective trial which is greatly needed in
these rare tumors.
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